phenylmethyl N-[2-(2,2,2-trifluoro-1-oxoethyl)phenyl]carbamate | 197783-74-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: phenylmethyl N-[2-(2,2,2-trifluoro-1-oxoethyl)phenyl]carbamate
• 英文别名: benzyl N-[2-(2,2,2-trifluoroacetyl)phenyl]carbamate
• CAS: 197783-74-7
• 化学式: C₁₆H₁₂F₃NO₃
• 分子量: 323.271
• InChiKey: GVTGOBZUZMKHEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Electrophilic ketones for the treatment of herpesvirus infections
  申请人：G. D. Searle & Co., Corporate Patent Department

  公开号：US20030119721A1

  公开（公告）日：2003-06-26

  A class of compounds is described which can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula II 1 wherein each of R 1 , R 2 , and R 3 is independently selected from hydrido, halo, and nitro; wherein R 8 is selected from haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted arylalkoxy and optionally substituted aryloxyalkyl; wherein Y is selected from fluoroalkyl, and 2 wherein R 9 is alkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

  描述了一类化合物，可用于治疗病毒感染。 特别感兴趣的化合物由Formula II1定义，其中R1、R2和R3中的每一个独立地选择自氢代基、卤素和硝基；其中R8选择自卤代烷基、可选地取代的芳基、可选地取代的芳基烷基、可选地取代的杂环芳基、可选地取代的芳基烷氧基和可选地取代的芳氧基烷基；其中Y选择自氟代烷基，以及其中R9是烷基氨基；或其药用可接受的盐或互变异构体。
• ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS
  申请人：G.D. SEARLE & CO.

  公开号：EP0888322A2

  公开（公告）日：1999-01-07
• US6673784B1
  申请人：——

  公开号：US6673784B1

  公开（公告）日：2004-01-06
• US6673788B2
  申请人：——

  公开号：US6673788B2

  公开（公告）日：2004-01-06
• [EN] ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS<br/>[FR] CETONES ELECTROPHILES POUR LE TRAITEMENT D'INFECTIONS A HERPESVIRUS
  申请人：——

  公开号：WO1997034566A2

  公开（公告）日：1997-09-25

  [EN] A class of compounds is described which can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula (II) wherein each of R<1>, R<2>, and R<3> is independently selected from hydrido, halo, and nitro; wherein R<8> is selected from haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted arylalkoxy and optionally substituted aryloxyalkyl; wherein Y is selected from fluoroalkyl, and (A); and wherein (R<9>) is alkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.